InflaRx NV
IFRX0.886USD
+0.026+3.08%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
56.13MCap. mercado
PérdidaP/E TTM
Más Datos de InflaRx NV Compañía
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
Información de la empresa
Símbolo de cotizaciónIFRX
Nombre de la empresaInflaRx NV
Fecha de salida a bolsaNov 08, 2017
Director ejecutivoProf. Niels C. Riedemann, M.D., Ph.D
Número de empleados74
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 08
DirecciónWinzerlaer Str. 2
CiudadJENA
Bolsa de valoresNASDAQ Global Select Consolidated
PaísGermany
Código postal07745
Teléfono493641508180
Sitio Webhttps://www.inflarx.de/
Símbolo de cotizaciónIFRX
Fecha de salida a bolsaNov 08, 2017
Director ejecutivoProf. Niels C. Riedemann, M.D., Ph.D
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Nicolas Fulpius
Mr. Nicolas Fulpius
Independent Chairman of the Board
Independent Chairman of the Board
467.92K
--
Mr. Richard Brudnick
Mr. Richard Brudnick
Non-Executive Independent Director
Non-Executive Independent Director
50.00K
--
Dr. Thomas Taapken
Dr. Thomas Taapken
Chief Financial Officer
Chief Financial Officer
3.50K
--
Ms. Hege Hellstrom
Ms. Hege Hellstrom
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Camilla Chong
Dr. Camilla Chong
Chief Medical Officer
Chief Medical Officer
--
--
Prof. Niels C. Riedemann, M.D., Ph.D
Prof. Niels C. Riedemann, M.D., Ph.D
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Mark Kubler
Mr. Mark Kubler
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Prof. Renfeng Guo
Prof. Renfeng Guo
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
--
--
Ms. Derval O'Carroll
Ms. Derval O'Carroll
Senior Vice President, Global Head of Regulatory Affairs and Compliance
Senior Vice President, Global Head of Regulatory Affairs and Compliance
--
--
Mr. Anthony Gibney
Mr. Anthony Gibney
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Nicolas Fulpius
Mr. Nicolas Fulpius
Independent Chairman of the Board
Independent Chairman of the Board
467.92K
--
Mr. Richard Brudnick
Mr. Richard Brudnick
Non-Executive Independent Director
Non-Executive Independent Director
50.00K
--
Dr. Thomas Taapken
Dr. Thomas Taapken
Chief Financial Officer
Chief Financial Officer
3.50K
--
Ms. Hege Hellstrom
Ms. Hege Hellstrom
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Camilla Chong
Dr. Camilla Chong
Chief Medical Officer
Chief Medical Officer
--
--
Prof. Niels C. Riedemann, M.D., Ph.D
Prof. Niels C. Riedemann, M.D., Ph.D
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Desglose de ingresos
Divisa: EURActualizado: mié., 5 de mar
Divisa: EURActualizado: mié., 5 de mar
FY2022
FY2021
FY2020
FY2019
Sin datos
Por regiónEUR
Nombre
Ganancia
Proporción
Germany
0.00
0.00%
United States
0.00
0.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mar., 29 de jul
Actualizado: mar., 29 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Suvretta Capital Management, LLC
9.66%
683 Capital Management LLC
3.91%
Guo (Renfeng M.D.)
2.62%
Eversept Partners, LP
2.50%
Morgan Stanley & Co. LLC
1.88%
Other
79.43%
Accionistas
Accionistas
Proporción
Suvretta Capital Management, LLC
9.66%
683 Capital Management LLC
3.91%
Guo (Renfeng M.D.)
2.62%
Eversept Partners, LP
2.50%
Morgan Stanley & Co. LLC
1.88%
Other
79.43%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
20.49%
Individual Investor
6.44%
Investment Advisor
3.05%
Research Firm
2.34%
Investment Advisor/Hedge Fund
0.39%
Venture Capital
0.06%
Other
67.23%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
85
22.00M
32.77%
-470.85K
2025Q1
87
22.59M
33.65%
+61.67K
2024Q4
86
18.09M
26.94%
-3.90M
2024Q3
81
17.30M
28.32%
-4.75M
2024Q2
83
17.63M
29.02%
-4.11M
2024Q1
87
18.26M
30.09%
-4.67M
2023Q4
91
21.52M
35.62%
-5.82M
2023Q3
89
23.41M
42.05%
-4.60M
2023Q2
95
25.76M
47.58%
+2.86M
2023Q1
90
10.99M
24.57%
-8.39M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Suvretta Capital Management, LLC
6.48M
9.66%
+750.00K
+13.08%
Mar 31, 2025
683 Capital Management LLC
2.63M
3.91%
+555.00K
+26.81%
Mar 31, 2025
Guo (Renfeng M.D.)
1.76M
2.62%
--
--
Dec 31, 2024
Eversept Partners, LP
1.68M
2.5%
+1.18M
+240.33%
Mar 31, 2025
Morgan Stanley & Co. LLC
1.26M
1.88%
-776.51K
-38.11%
Mar 31, 2025
SilverArc Capital Management, LLC
1.16M
1.73%
+1.16M
--
Mar 31, 2025
Riedemann (Niels C. M.D.)
1.07M
1.59%
--
--
Dec 31, 2024
Mark (Christian Kubler)
960.01K
1.43%
--
--
Dec 31, 2024
Woodline Partners LP
750.98K
1.12%
+750.98K
--
Mar 31, 2025
StemPoint Capital LP
725.02K
1.08%
+725.02K
--
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
ALPS Medical Breakthroughs ETF
0%
Invesco Raymond James SB-1 Equity ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
ALPS Medical Breakthroughs ETF
Proporción0%
Invesco Raymond James SB-1 Equity ETF
Proporción0%
Invesco NASDAQ Future Gen 200 ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
